Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects. Its ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system, where inflammation is stimulated at the tumor site and the cytotoxic T-lymphocyte response, where immune system cells are primed to recognize and kill specific cells. The Moditope immunotherapy platform is based on exploiting the normal immune response to stressed cells, mediated by cluster of differentiation 4+ T cells, and harnessing this mechanism to eradicate cancer cells.
Show more
Type
Public
HQ
Nottingham, GB
Size (employees)
10 (est)
Scancell Holdings is headquartered in Nottingham, GB
Report incorrect company information

Scancell Holdings Office Locations

Scancell Holdings has an office in Nottingham
Nottingham, GB (HQ)
Department of Clinical Oncology City Hospital Hucknall Road
Show all (1)
Report incorrect company information

Scancell Holdings Financials and Metrics

Scancell Holdings Financials

Scancell Holdings's revenue was reported to be £231 in FY, 2008
GBP

Net income (FY, 2017)

(3.5 m)

EBITDA (FY, 2017)

(4.5 m)

EBIT (FY, 2017)

(4.5 m)

Market capitalization (31-Oct-2017)

39 m

Closing share price (31-Oct-2017)

0.1

Cash (30-Apr-2017)

2.7 m
Scancell Holdings's current market capitalization is £39 m.
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

231

Cost of goods sold

241.3 k713.3 k1.1 m

Gross profit

(241 k)

Gross profit Margin, %

(104342%)
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

997.7 k1.5 m2.8 m1.1 m3.5 m1.5 m5.6 m3.1 m6.5 m2.7 m

Accounts Receivable

8 8

Current Assets

1 m1.9 m3 m1.2 m3.7 m1.9 m6.1 m3.9 m7.1 m3.5 m

PP&E

86.7 k82.3 k131.8 k98.9 k106.3 k131.7 k115.6 k86.5 k64.6 k93.1 k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(405.3 k)(660 k)(1.7 m)(1.6 m)(1.9 m)(1.9 m)(2.2 m)(2.4 m)(2.6 m)(3.5 m)

Cash From Operating Activities

(439.4 k)(1.2 m)(1.5 m)(1.8 m)859.6 k(2 m)(2.1 m)(2.6 m)(3 m)(4.5 m)

Cash From Financing Activities

20.8 k1.7 m2.7 m48 k1.6 m6.2 m5.8 m

Net Change in Cash

(507.2 k)521.3 k1.3 m(1.7 m)2.4 m(2 m)4.1 m(2.5 m)3.5 m(3.9 m)
GBPY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Scancell Holdings Online and Social Media Presence

Embed Graph
Report incorrect company information